PF-06424439 methanesulfonate is primarily used in the field of pharmaceutical research and development. It is specifically investigated for its potential as an inhibitor of diacylglycerol acyltransferase 2 (DGAT2), an enzyme involved in triglyceride synthesis. By targeting DGAT2, this compound is studied for its ability to modulate lipid metabolism, making it a candidate for the treatment of metabolic disorders such as hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), and other conditions associated with abnormal lipid accumulation. Its application extends to preclinical studies where researchers evaluate its efficacy, safety, and pharmacokinetic properties to determine its suitability for further clinical development. Additionally, it serves as a tool compound in biochemical assays to better understand the role of DGAT2 in lipid homeostasis and related metabolic pathways.